Rapport Therapeutics (RAPP) Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Current Assets for 4 consecutive years, with $484.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 66.58% year-over-year to $484.7 million; the TTM figure through Mar 2026 stood at $484.7 million (up 66.58% YoY), while the FY2025 annual figure was $498.6 million, up 60.93% from the prior year.
• Current Assets retreated to $484.7 million in Q1 2026 per RAPP's latest filing, from $498.6 million in the prior quarter.
• Across five years, Current Assets topped out at $520.7 million in Q3 2025 and bottomed at $150.9 million in Q4 2023.
• Historically, Current Assets has averaged $354.7 million across 4 years, with a median of $325.9 million in 2024.
• Annual changes were most pronounced in 2024 — Current Assets soared 105.34% — and 2025, when it declined 20.67%.
• Rapport Therapeutics' Current Assets stood at $150.9 million in 2023, then soared by 105.34% to $309.8 million in 2024, then surged by 60.93% to $498.6 million in 2025, then fell by 2.78% to $484.7 million in 2026.
• Business Quant data shows RAPP's Current Assets at $484.7 million in Q1 2026, $498.6 million in Q4 2025, and $520.7 million in Q3 2025.